Evidence map›Paper›PMID 28820442›Full record

ArticleNanomaterials (Basel, Switzerland)2017

Tuning Properties of Iron Oxide Nanoparticles in Aqueous Synthesis without Ligands to Improve MRI Relaxivity and SAR.

Debora Bonvin, Duncan T L Alexander, Angel Millán, Rafael Piñol, Beatriz Sanz, Gerardo F Goya, Abelardo Martínez, Jessica A M Bastiaansen, Matthias Stuber, Kurt J Schenk and 2 more

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Nanomaterials (Basel, Switzerland) · 2019
    Article
  13. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2018
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Debora BonvinPowder Technology Laboratory, Institute of Matesrials, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. debora.bonvin@epfl.ch.
Duncan T L AlexanderInterdisciplinary Centre for Electron Microscopy (CIME), Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. duncan.alexander@epfl.ch.
Angel MillánInstituto de Ciencia de Materiales de Aragón, Universidad de Zaragoza, C/Pedro Cerbuna 10, 50009 Zaragoza, Spain. amillan@unizar.es.
Rafael PiñolInstituto de Ciencia de Materiales de Aragón, Universidad de Zaragoza, C/Pedro Cerbuna 10, 50009 Zaragoza, Spain. pinol@unizar.es.
Beatriz SanzInstituto de Nanociencia de Aragón, Universidad de Zaragoza, Mariano Esquillor s/n, 50018 Zaragoza, Spain. beasanz@unizar.es.
Gerardo F GoyaInstituto de Nanociencia de Aragón, Universidad de Zaragoza, Mariano Esquillor s/n, 50018 Zaragoza, Spain. goya@unizar.es.
Abelardo MartínezGrupo de Electrónica de Potencia y Microelectrónica, I3A, Universidad de Zaragoza, 50018 Zaragoza, Spain. amiturbe@unizar.es.
Jessica A M BastiaansenDepartment of Radiology, University Hospital (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland. jbastiaansen.mri@gmail.com.
Matthias StuberDepartment of Radiology, University Hospital (CHUV) and University of Lausanne (UNIL), 1011 Lausanne, Switzerland. Matthias.Stuber@chuv.ch.
Kurt J SchenkCCC-IPSB, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. kurt.schenk@epfl.ch.
Heinrich HofmannPowder Technology Laboratory, Institute of Matesrials, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. heinrich.hofmann@epfl.ch.
Marijana Mionić EbersoldPowder Technology Laboratory, Institute of Matesrials, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. marijanamionic@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aqueous synthesis without ligands of iron oxide nanoparticles (IONPs) with exceptional properties still remains an open issue, because of the challenge to control simultaneously numerous properties of the IONPs in these rigorous settings. To solve this, it is necessary to correlate the synthesis process with their properties, but this correlation is until now not well understood. Here, we study and correlate the structure, crystallinity, morphology, as well as magnetic, relaxometric and heating properties of IONPs obtained for different durations of the hydrothermal treatment that correspond to the different growth stages of IONPs upon initial co-precipitation in aqueous environment without ligands. We find that their properties were different for IONPs with comparable diameters. Specifically, by controlling the growth of IONPs from primary to secondary particles firstly by colloidal and then also by magnetic interactions, we control their crystallinity from monocrystalline to polycrystalline IONPs, respectively. Surface energy minimization in the aqueous environment along with low temperature treatment is used to favor nearly defect-free IONPs featuring superior properties, such as high saturation magnetization, magnetic volume, surface crystallinity, the transversal magnetic resonance imaging (MRI) relaxivity (up to

Indexed as

aqueous synthesishydrothermal treatmentiron oxide nanoparticlesmagnetic nanoparticleMRI relaxivitysaturation magnetizationspecific absorption rate

Identifiers

PMID28820442
PMCPMC5575707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.